A Biobank Collecting Samples From People With Malignant Hypertension
Stores biological samples from adults treated for severe, dangerously high blood pressure.
Key facts
- Who runs it
- Centre Hospitalier de PAU
- Where
- Annecy, Bordeaux, Chalon-sur-Saône, Lyon, Paris, Strasbourg, Toulouse, Tours, and Valenciennes, FranceSee the 11 sites
- Trial code
- Registry title
- Determinants of Malignant Hypertension Onset and Related Target Organ Damages: the HAMA Biobank
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 19 Mar 2026
- Expected to end
- 1 Apr 2036
- Type of study
- Observational
- Treatments tested
- biobank
- Record updated
- 22 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in the HAMA cohort who have malignant hypertension, meaning very high blood pressure with serious organ damage. Blood and other samples are collected and stored.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Malignant hypertension: severe hypertension with severe hypertensive retinopathy, or severe hypertension with acute damage to organs caused by high blood pressure
Main reasons for not taking part
- Refusal to take part in the HAMA bank substudy
- Being on chronic dialysis
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- patients included in the HAMA cohort with the following critera :; Malignant hypertension according to the classic definition (Severe hypertension associated with severe hypertensive retinopathy); Severe hypertension associated with acute target organ damage due to high blood pressure
Who cannot take part
- Refusal to participate to the substudy " HAMA bank "
- patient on chronic dialysis
Where in France
- CH d'ANNECYAnnecy, FranceContact: Sandra JOST TURILLOTTaking people
- CHU de BordeauxBordeaux, FranceContact: Romain BOULESTREAUTaking people
- CH de Chalon sur SaôneChalon-sur-Saône, FranceContact: Magali LOUISTaking people
- Hospices Civils de LyonLyon, FranceContact: Pierre Yves COURANDNot yet recruiting
- APHP AvicenneParis, FranceContact: Marilucy LOPEZ SUBLETTaking people
- Hôpital Européen Georges PompidouParis, FranceContact: Aurélien LORTHIOIRTaking people
- Hôpital Paris Saint JosephParis, FranceContact: Yara HANON - ANTAKLYTaking people
- CHU de StrasbourgStrasbourg, FranceContact: Dominique STEPHANTaking people
- CHU de ToulouseToulouse, FranceContact: Béatrice DULY-BOUHANICKTaking people
- CHRU de ToursTours, FranceContact: Jean Michel HALIMITaking people
- CH de ValenciennesValenciennes, FranceContact: Claire CARTERYTaking people
About the trial
What the trial wants to find out
The HAMA bank is an initiative aimed at collecting, preparing, and storing biological samples from patients treated for malignant hypertension and included in the HAMA cohort. Conducted under CRB (ISO20387) conditions, this biobank serves as an essential resource for understanding the disease's pathophysiology, as well as for identifying novel biomarkers and therapeutic targets
Treatments tested
- biobank
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Determinants of Malignant Hypertension Onset and Related Target Organ Damages: the HAMA Biobank
- Plain-language title
- A Biobank Collecting Samples From People With Malignant HypertensionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 22 October 2026